IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene CEACAM1 Ensembl ENSG00000079385 Chromosome 19 Start 47701340 End 47724479
Description Carcinoembryonic antigen-related cell adhesion molecule 1 Precursor (Biliary glycoprotein 1)(BGP-1)(CD66a antigen) [Source:UniProtKB/Swiss-Prot;Acc:P13688]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 1814
     Entrez Gene : 634
     UCSC : uc002otv.2
     GeneCards : 1814
     RefSeq : NM_001024912
     CCDS : CCDS12609.1
     Uniprot : P13688
     Interpro : P13688
     OMIM : 109770
     GeneTests : CEACAM1
     CGAP : CEACAM1
     PMID : 2457922

< Top >


Experimental Evidence        (help)
Expression Sample Number Method Clinical information PubMed Reference
up 72/145(50%) IHCTumor histology(P=0.017)//Kaplan-Meier analysis(pT3-pT4)(P=0.009)//Kaplan-Meier analysis(pN1-pN2)(P=0.024) 12796394 Clin Cancer Res. 2003 Jun;9(6):2260-6.

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  36082_at  1.28  2.29e-8  2.16e-7  -0.28  2.64e-1  3.64e-1
 HG_U95  988_at  1.08  4.28e-7  3.05e-6  -0.20  2.62e-1  3.61e-1
 HG_U133A  206576_s_at  0.96  7.84e-29  1.13e-27  -0.30  8.60e-4  9.61e-4
 HG_U133A  209498_at  1.17  3.31e-19  2.46e-18  3.23  1.04e-113  1.04e-112
 HG_U133A  210610_at  0.33  3.90e-3  6.51e-3  0.55  9.86e-8  1.19e-7
 HG_U133A  211883_x_at  0.50  1.38e-8  4.30e-8  -2.87  1.37e-56  3.48e-56
 HG_U133A  211889_x_at  0.56  6.20e-8  1.81e-7  2.64  3.90e-95  2.31e-94
 HG_U133_Plus2  206576_s_at  1.13  6.95e-17  1.17e-15  0.80  6.22e-9  2.41e-8
 HG_U133_Plus2  209498_at  1.02  1.21e-7  6.36e-7  -0.60  9.50e-3  1.56e-2
 HG_U133_Plus2  210610_at  0.42  1.09e-2  2.20e-2  0.06  7.14e-1  7.58e-1
 HG_U133_Plus2  211883_x_at  1.12  8.76e-11  7.03e-10  0.54  5.72e-4  1.14e-3
 HG_U133_Plus2  211889_x_at  0.87  2.71e-6  1.14e-5  -0.28  1.76e-1  2.23e-1
 Stanford  14403  0.81  1.41e-1  3.12e-1  -0.67  1.46e-1  3.49e-1
 Agilent_HS_21.6K  12239  0.04  1.79e-1  3.48e-1  0.04  2.72e-1  4.27e-1

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  206576_s_at  0.22  4.80e-1  9.25e-1  -0.17  5.41e-1  1.00e+0
 HG_U133A  209498_at  -0.36  4.15e-1  9.07e-1  -0.17  4.93e-1  1.00e+0
 HG_U133A  210610_at  -0.88  9.65e-2  7.69e-1  -0.08  7.82e-1  1.00e+0
 HG_U133A  211883_x_at  -0.03  9.18e-1  9.95e-1  -0.49  4.31e-2  1.00e+0
 HG_U133A  211889_x_at  -0.26  4.42e-1  9.13e-1  -0.40  1.21e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 36082_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 988_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 206576_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 209498_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 210610_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 211883_x_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 211889_x_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 206576_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 209498_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 210610_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 211883_x_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 211889_x_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 14403    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 12239    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
cd66a melanoma CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. 11884449 Human
cd66a melanoma The lack of killing is shown to be the result of homotypic CD66a interactions between the melanoma line and the NK cells. 11884449 Human
cd66a malignant melanoma Finally, the expression of CD66a protein was observed on NK cells derived from patients with malignant melanoma. 11884449 Human
cd66a multiple myeloma Expression of CD66a in multiple myeloma. 11948796 Human
cd66a myeloma Expression of CD66a in myeloma cells was examined with mAb TS135 against CD66a transfectants of murine-transformed fibroblasts. 11948796 Human
cd66a myeloma CD66a in myeloma cells was considered to be detectable with this mAb, since CD66c and CD66e are not expressed in them. 11948796 Human
cd66a myeloma CD66a was detected in three myeloma cell lines and an IgM-producing B-cell line. 11948796 Human
cd66a multiple myeloma In clinical bone marrow specimens, including 18 multiple myeloma, two primary macroglobulinemia, and a case of CLL-like chronic lymphoproliferation with monoclonal IgG production, CD66a and three conventional myeloma cell markers (PCA-1, CD38, and CD56) w 11948796 Human
cd66a primary macroglobulinemia In clinical bone marrow specimens, including 18 multiple myeloma, two primary macroglobulinemia, and a case of CLL-like chronic lymphoproliferation with monoclonal IgG production, CD66a and three conventional myeloma cell markers (PCA-1, CD38, and CD56) w 11948796 Human
cd66a myeloma In clinical bone marrow specimens, including 18 multiple myeloma, two primary macroglobulinemia, and a case of CLL-like chronic lymphoproliferation with monoclonal IgG production, CD66a and three conventional myeloma cell markers (PCA-1, CD38, and CD56) w 11948796 Human
cd66a multiple myeloma The findings suggest that CD66a is expressed in multiple myeloma with high frequency. 11948796 Human
cd66a breast cancer Expression of the adhesion molecule CEACAM1 (CD66a, BGP, C-CAM) in breast cancer is associated with the expression of the tumor-suppressor genes Rb, Rb2, and p27. 11964043 Human
bgp breast cancer Expression of the adhesion molecule CEACAM1 (CD66a, BGP, C-CAM) in breast cancer is associated with the expression of the tumor-suppressor genes Rb, Rb2, and p27. 11964043 Human
ceacam1 breast cancer Expression of the adhesion molecule CEACAM1 (CD66a, BGP, C-CAM) in breast cancer is associated with the expression of the tumor-suppressor genes Rb, Rb2, and p27. 11964043 Human
cd66a tumor The adhesion molecule CEACAM1 (CD66a, BGP, C-CAM) is not only involved in maintaining normal tissue architecture, but also acts as a tumor suppressor in several experimental systems where loss of CEACAM1 expression results in enhanced tumor-cell growth an 11964043 Human
bgp tumor The adhesion molecule CEACAM1 (CD66a, BGP, C-CAM) is not only involved in maintaining normal tissue architecture, but also acts as a tumor suppressor in several experimental systems where loss of CEACAM1 expression results in enhanced tumor-cell growth an 11964043 Human
ceacam1 tumor The adhesion molecule CEACAM1 (CD66a, BGP, C-CAM) is not only involved in maintaining normal tissue architecture, but also acts as a tumor suppressor in several experimental systems where loss of CEACAM1 expression results in enhanced tumor-cell growth an 11964043 Human
ceacam1 breast cancer In order to further analyze the role of CEACAM1 in the development of breast cancer, we performed Western-blot analysis and immunohistochemistry with highly specific monoclonal antibodies in a cohort of 68 mammary carcinomas which had also been analyzed f 11964043 Human
ceacam1 mammary carcinomas In order to further analyze the role of CEACAM1 in the development of breast cancer, we performed Western-blot analysis and immunohistochemistry with highly specific monoclonal antibodies in a cohort of 68 mammary carcinomas which had also been analyzed f 11964043 Human
ceacam1 human prostate cancer Down-regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition. 11979369 Human
ceacam1 prostate cancer One of these is CEACAM1, which has been found to be downregulated in several carcinomas, including prostate cancer. 11979369 Human
ceacam1 carcinomas One of these is CEACAM1, which has been found to be downregulated in several carcinomas, including prostate cancer. 11979369 Human
ceacam1 cancer Occludin was also lost in polygonal (ie, unpolarized) cells of Gleason grades 4 and 5, but remained expressed in all cells facing a lumen in all grades of cancer, which CEACAM1 was not. 11979369 Human
ceacam1 prostate cancer In conclusion, downregulation of CEACAM1 as well as that of occludin in prostate cancer is associated with loss of cell polarity. 11979369 Human
ceacam1 carcinoma The proliferative activity, measured as Ki67 labeling index, showed a fourfold increase in the carcinoma cells with lost CEACAM1 expression, supporting previous observations that CEACAM1 regulates cell proliferation. 11979369 Human
ceacam1 prostate carcinoma Immunohistochemical analysis of CEACAM1 expression patterns may be useful in assessment of the malignant potential of prostate carcinoma. 11979369 Human
ceacam1 cutaneous malignant melanoma CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. 12011132 Human
ceacam1 metastatic disease CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. 12011132 Human
ceacam1 prostate carcinomas CEACAM1 downregulation has been demonstrated in colorectal and prostate carcinomas. 12011132 Human
ceacam1 metastasis PATIENTS AND METHODS: CEACAM1 expression was immunohistochemically evaluated in 100 primary cutaneous malignant melanomas and correlated with metastasis in a 10-year follow-up. 12011132 NA
ceacam1 primary cutaneous malignant melanomas PATIENTS AND METHODS: CEACAM1 expression was immunohistochemically evaluated in 100 primary cutaneous malignant melanomas and correlated with metastasis in a 10-year follow-up. 12011132 NA
ceacam1 metastases Furthermore, CEACAM1 expression was analyzed in metastatic lesions (11 distant metastases and six sentinel lymph node metastases). 12011132 Human
ceacam1 lymph-node metastases Furthermore, CEACAM1 expression was analyzed in metastatic lesions (11 distant metastases and six sentinel lymph node metastases). 12011132 Human
ceacam1 metastasis Kaplan-Meier analysis revealed a highly significant association between CEACAM1 expression and metastasis (P <.0001); multivariate Cox regression analysis, including CEACAM1 expression status adjusted for tumor thickness, presence of ulceration, and mitot 12011132 Human
ceacam1 tumor Kaplan-Meier analysis revealed a highly significant association between CEACAM1 expression and metastasis (P <.0001); multivariate Cox regression analysis, including CEACAM1 expression status adjusted for tumor thickness, presence of ulceration, and mitot 12011132 Human
ceacam1 metastatic disease CONCLUSION: Expression of the cell adhesion molecule CEACAM1 in the primary tumors in melanoma patients is associated with the subsequent development of metastatic disease. 12011132 Human
ceacam1 primary tumors CONCLUSION: Expression of the cell adhesion molecule CEACAM1 in the primary tumors in melanoma patients is associated with the subsequent development of metastatic disease. 12011132 Human
ceacam1 melanoma CONCLUSION: Expression of the cell adhesion molecule CEACAM1 in the primary tumors in melanoma patients is associated with the subsequent development of metastatic disease. 12011132 Human
cd66 leukemias Radiolabeled monoclonal antibodies have been used with encouraging results in conjunction with stem cell transplantation for patients with hematologic malignancies targeting a variety of surface antigens including CD33, CD45 and CD66 for leukemias, CD20 a 12058230 Human
cd66 non-hodgkin's lymphomas Radiolabeled monoclonal antibodies have been used with encouraging results in conjunction with stem cell transplantation for patients with hematologic malignancies targeting a variety of surface antigens including CD33, CD45 and CD66 for leukemias, CD20 a 12058230 Human
cd66 hematologic malignancies Radiolabeled monoclonal antibodies have been used with encouraging results in conjunction with stem cell transplantation for patients with hematologic malignancies targeting a variety of surface antigens including CD33, CD45 and CD66 for leukemias, CD20 a 12058230 Human
ceacam1 tumor angiogenesis Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. 12122002 Human
ceacam1 tumor Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. 12122002 Human
ceacam1 tumor We have previously shown that CEACAM1, a cell-adhesion molecule, acts as a tumor suppressor in prostate carcinoma. 12122002 Human
ceacam1 prostate carcinoma We have previously shown that CEACAM1, a cell-adhesion molecule, acts as a tumor suppressor in prostate carcinoma. 12122002 Human
ceacam1 prostate cancer Expression of CEACAM1 in prostate cancer cells suppresses their growth in vivo. 12122002 Human
ceacam1 prostate cancer However, CEACAM1 has no effect on the growth of prostate cancer cells in vitro. 12122002 Human
ceacam1 tumor angiogenesis This difference suggests that the antitumor effect of CEACAM1 may be due to inhibition of tumor angiogenesis, perhaps by increased secretion of antiangiogenic molecules from the cells. 12122002 Human
ceacam1 prostate cancer In this study, we have demonstrated that expression of CEACAM1 in DU145 prostate cancer cells induced the production of a factor or factors that specifically blocked the growth of endothelial but not epithelial cells. 12122002 Human
ceacam1 tumor Only medium conditioned by CEACAM1 mutants that were able to suppress tumor growth in vivo could cause endothelial cell apoptosis. 12122002 Human
ceacam1 tumor angiogenesis These observations suggest that CEACAM1-mediated tumor suppression in vivo is, at least in part, due to the ability of CEACAM1 to inhibit tumor angiogenesis. 12122002 Human
ceacam1 tumor These observations suggest that CEACAM1-mediated tumor suppression in vivo is, at least in part, due to the ability of CEACAM1 to inhibit tumor angiogenesis. 12122002 Human
ceacam1 carcinoma in situ CEACAM1 immunostaining is significantly increased and extends to the basal part of Sertoli cells in the presence of carcinoma in situ. 14985475 Human
ceacam1 germ cell tumours Additionally, CEACAM1 is apparently involved in the angiogenesis of germ cell tumours. 14985475 Human
bgp early gastric cancer BGP expression in gastric epithelium and early gastric cancer. 12378336 Human
ceacam1 adenocarcinoma of the lung Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. 12409325 Human
ceacam1 adenocarcinomas PURPOSE: To evaluate the prognostic relevance of CEACAM1 and sialyl Lewis X expression in adenocarcinomas of the lung. 12409325 NA
ceacam1 tumor In multivariate Cox regression analysis, next to tumor stage and sex, only the expression of CEACAM1 was a significant independent prognostic factor for survival. 12409325 Human
ceacam1 adenocarcinomas CONCLUSION: Expression of CEACAM1 was an independent prognostic factor in our patient population and can be used to stratify patients with adenocarcinomas of the lung into low-risk and high-risk groups. 12409325 Human
ceacam1 tumors In contrast, the expression of sialyl Lewis X was of no prognostic relevance because it was expressed in 97% of all investigated tumors, and most likely has no influence on the function of CEACAM1 in this tumor entity. 12409325 Human
ceacam1 tumor In contrast, the expression of sialyl Lewis X was of no prognostic relevance because it was expressed in 97% of all investigated tumors, and most likely has no influence on the function of CEACAM1 in this tumor entity. 12409325 Human
ceacam1 tumor Importantly, the patients' NK cells use the CEACAM1 protein to inhibit the killing of tumor and autologous cells. 14604968 Human
ceacam1 carcinomas The intercellular adhesion molecule CEACAM1, also known as C-CAM1 (where CAM is cell-adhesion molecule), can function as a tumour suppressor in several carcinomas, including those of the prostate, breast, bladder and colon. 11284729 Human
cd66a tumors CEACAM1 (CD66a, BGP, C-CAM) is an adhesion molecule of the carcinoembryonic antigen (CEA) family which has been shown to be normally expressed at the apical pole of epithelial cells and to show a dysregulated expression pattern in tumors derived from the 11293162 Human
bgp tumors CEACAM1 (CD66a, BGP, C-CAM) is an adhesion molecule of the carcinoembryonic antigen (CEA) family which has been shown to be normally expressed at the apical pole of epithelial cells and to show a dysregulated expression pattern in tumors derived from the 11293162 Human
ceacam1 tumors CEACAM1 (CD66a, BGP, C-CAM) is an adhesion molecule of the carcinoembryonic antigen (CEA) family which has been shown to be normally expressed at the apical pole of epithelial cells and to show a dysregulated expression pattern in tumors derived from the 11293162 Human
cd66a breast cancers CEACAM1 (also known as biliary glycoprotein, C-CAM or CD66a) is a cell adhesion molecule of the immunoglobulin family behaving as a tumor inhibitory protein in colon, prostate, liver, endometrial and breast cancers. 11313949 Human
ceacam1 breast cancers CEACAM1 (also known as biliary glycoprotein, C-CAM or CD66a) is a cell adhesion molecule of the immunoglobulin family behaving as a tumor inhibitory protein in colon, prostate, liver, endometrial and breast cancers. 11313949 Human
ceacam1 tumor Inhibition of tumor development is dependent upon the presence of the long 71-73 amino acid cytoplasmic domain of the CEACAM1 protein (CEACAM1-L). 11313949 Human
ceacam1 colon tumors In addition, CEACAM1 was also shown to suppress the growth of prostate, breast, and colon tumors. 11278391 Human
ceacam1 prostate cancer Although expression of CEACAM1's cytoplasmic domain inhibited the growth of DU145 prostate cancer cells in vivo, mutation of serine 503 to alanine abolished the growth-inhibitory activity. 11278391 Human
ceacam1 tumour By mutation analysis, we identified a 1 bp deletion in a (T)(8) microsatellite embedded in the 1801 nucleotide long 3'-UTR of CEACAM1 gene, thought to be involved in tumour onset and progression. 14602915 Human
bgp tumor PURPOSE: Biliary glycoprotein (BGP), a member of the carcinoembryonic antigen (CEA) gene family, is produced by hepatocytes, and is suggested to function as a cell adhesion molecule, mouse hepatitis virus receptor, and tumor suppressor. 11480791 Human
ceacam1 tumor CEACAM1 has cell adhesion activity and acts as a signaling molecule, and long-tail isoforms inhibit the growth of colon and prostate tumor cells in rodents. 11483763 Mouse
ceacam1 tumor CEACAM1 is a cell adhesion molecule that has been implicated in a number of physiological processes (eg, tumor suppressor in epithelial tissues, potent angiogenic factor in microvessel formation, microbial receptor in human granulocytes and epithelial cel 11485912 Human
ceacam1 tumor CEACAM1 on leukocytic, endothelial, and epithelial cells functions in homophilic adhesion, tumor suppression, regulating cell adhesion and proliferation, and in heterophilic adhesion as a receptor for E-selectin and Neisseria meningiditis, Neisseria gonor 11520797 Human
ceacam1 prostate cancer Previous studies have established that the cell-cell adhesion molecule-1 (CEACAM1, previously known as C-CAM1) functions as a tumor suppressor in prostate cancer and is involved in the regulation of prostate growth and differentiation. 11694347 Human
ceacam1 tumor Previous studies have established that the cell-cell adhesion molecule-1 (CEACAM1, previously known as C-CAM1) functions as a tumor suppressor in prostate cancer and is involved in the regulation of prostate growth and differentiation. 11694347 Human
bgp colorectal cancers Four members of the carcinoembryonic antigen (CEA) family, CEA, CEACAM1 (BGP), CEACAM6 (NCA-50/90), and CEACAM7 (CGM2), are coexpressed in normal colorectal epithelia but are deregulated in colorectal cancers, where they could play a role in tumorigenesis 10666389 Human
ceacam1 colorectal cancers Four members of the carcinoembryonic antigen (CEA) family, CEA, CEACAM1 (BGP), CEACAM6 (NCA-50/90), and CEACAM7 (CGM2), are coexpressed in normal colorectal epithelia but are deregulated in colorectal cancers, where they could play a role in tumorigenesis 10666389 Human
ceacam1 tumor The tumor growth-inhibiting cell adhesion molecule CEACAM1 (C-CAM) is differently expressed in proliferating and quiescent epithelial cells and regulates cell proliferation. 10728682 Human
ceacam1 tumor angiogenesis Since CEACAM1 is expressed in tumor microvessels but not in large blood vessels, CEACAM1 may be a target for the inhibition of tumor angiogenesis. 10882072 Human
ceacam1 tumor Since CEACAM1 is expressed in tumor microvessels but not in large blood vessels, CEACAM1 may be a target for the inhibition of tumor angiogenesis. 10882072 Human
cd66 acute leukaemia CD66 expression in acute leukaemia. 10901608 Human
cd66 acute-lymphocytic leukaemia (all) Despite being usually restricted to cells of myeloid or monocytic origin, CD66 expression has also been reported in blasts from children with B-cell lineage acute lymphocytic leukaemia (ALL). 10901608 Human
cd66 acute leukaemia An analysis of the CD66 expression was undertaken in a series of acute leukaemia patients. 10901608 Human
cd66 chronic myelocytic leukaemia (cml) CD66 was expressed in 2 of 29 patients with AML (acute myeloblastic leukemia) (6.8%) and in 8 of 12 patients with B-cell lineage ALL (66.7%; P<0.001); in blast crisis (BC) of chronic myelocytic leukaemia (CML), CD66 was expressed in two patients with lymp 10901608 Human
cd66 acute myeloblastic leukemia CD66 was expressed in 2 of 29 patients with AML (acute myeloblastic leukemia) (6.8%) and in 8 of 12 patients with B-cell lineage ALL (66.7%; P<0.001); in blast crisis (BC) of chronic myelocytic leukaemia (CML), CD66 was expressed in two patients with lymp 10901608 Human
cd66 blast crisis CD66 was expressed in 2 of 29 patients with AML (acute myeloblastic leukemia) (6.8%) and in 8 of 12 patients with B-cell lineage ALL (66.7%; P<0.001); in blast crisis (BC) of chronic myelocytic leukaemia (CML), CD66 was expressed in two patients with lymp 10901608 Human
ceacam1 cancers Human carcinoembryonic antigen (CEA), a widely used tumor marker, and CEACAM6 [formerly nonspecific cross-reacting antigen (NCA)] are up-regulated in many types of human cancers, whereas family member CEACAM1 [formerly biliary glycoprotein (BGP)] is usual 10910050 Human
ceacam1 tumor We identified phosphorylated Tyr-488-a residue in the cytoplasmic CEACAM1 domain known to be essential for the tumor suppressive effect-to be necessary for this association. 11035932 Human
ceacam1 human tumors The carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a member of the immunoglobulin superfamily, is expressed in microvessels of proliferating tissues such as endometrium, in tissues after wounding, and in solid human tumors. 11082271 Human
bgp breast tumor In contrast, the BGP-negative MCF7 breast tumor cell line, which does not form acini when grown in matrigel, exhibits >60% cell death with the occasional formation of acini, when transfected with the BGP sense gene and grown in Matrigel. 10564638 Human
bgp mcf7 breast cancer The lack of expression of BGP in the MCF7 breast cancer cell line suggests that the downregulation of BGP expression confers a growth advantage to these cells in ECM. 10564638 Human
cd66a tumor Biliary glycoprotein (Bgp, C-CAM, or CD66a) is an immunoglobulin-like cell adhesion molecule and functions as a tumor suppressor protein. 9867848 Human
bgp tumor Biliary glycoprotein (Bgp, C-CAM, or CD66a) is an immunoglobulin-like cell adhesion molecule and functions as a tumor suppressor protein. 9867848 Human
bgp1 breast tumor We have previously shown that the Bgp1 isoform responsible for inhibition of colonic, liver, prostate, and breast tumor cell growth contains within its cytoplasmic domain two tyrosine residues positioned in immunoreceptor tyrosine-based inhibition motif ( 9867848 Human
ceacam1 myeloma Two soluble ectodomain isoforms of CEACAM1 expressed in myeloma cells were immunologically active and highly glycosylated. 15110777 Human
ceacam1 tumor CEACAM1, a tumor suppressor (previously known as pp120), is a plasma membrane protein that undergoes phosphorylation on Tyr(488) in its cytoplasmic tail by the insulin receptor tyrosine kinase. 11694516 Human
cd66a prostate cancer Tumor-suppressive activity of CD66a in prostate cancer. 10419049 Mouse
cd66a tumors We have observed previously that CD66a protein expression is lost in most prostate tumors, suggesting that the down-regulation of CD66a is associated with the abnormal growth of prostate cells. 10419049 Human
cd66a tumor This homology suggests the possibility that CD66a might also be a tumor suppressor. 10419049 Human
cd66a du145 human prostate cancer In this report, we show that restoring CD66a expression in DU145 human prostate cancer cells by adenovirus (Ad)-mediated gene transfer dramatically altered the malignant phenotype of these cells, as evidenced by their reduced ability to form tumors in a x 10419049 Mouse
cd66a tumors In this report, we show that restoring CD66a expression in DU145 human prostate cancer cells by adenovirus (Ad)-mediated gene transfer dramatically altered the malignant phenotype of these cells, as evidenced by their reduced ability to form tumors in a x 10419049 Mouse
cd66a prostate cancer This result suggests that loss of CD66a protein plays an important role in the development of prostate cancer, and that restoring CD66a expression might provide an effective treatment for prostate cancer. 10419049 Human
cd66a prostate cancer We further explored the possibility of using Ad vectors to deliver CD66a as a potential therapeutic agent for prostate cancer. 10419049 Human
cd66a tumors Direct injection of Ad-CD66a, an Ad vector carrying the CD66a gene, into DU145 tumors in mice significantly suppressed the growth of these tumors. 10419049 Mouse
cd66a prostate cancer These results suggest that CD66a has tumor-suppressive activity and that Ad-CD66a is a potential therapeutic agent for prostate cancer treatment. 10419049 Mouse
ceacam1 breast cancer Treatment of breast cancer cells with MIS and interferon gamma (IFN-gamma) co-stimulated IRF-1 and CEACAM1 expression and synergistic induction of CEACAM1 by a combination of MIS and IFN-gamma was impaired by antisense IRF-1 expression. 14532292 Human
ceacam1 tumor cis-Determinants in the cytoplasmic domain of CEACAM1 responsible for its tumor inhibitory function. 10523833 Mouse
ceacam1 tumor CEACAM1 is involved in intercellular adhesion, signal transduction and tumor cell growth regulation. 10523833 Human
ceacam1 hepatic tumors CEACAM1 is down-regulated in colon and prostate carcinomas, as well as in endometrial, bladder and hepatic tumors, and 30% of breast cancers. 10523833 Human
ceacam1 prostate carcinomas CEACAM1 is down-regulated in colon and prostate carcinomas, as well as in endometrial, bladder and hepatic tumors, and 30% of breast cancers. 10523833 Human
ceacam1 breast cancers CEACAM1 is down-regulated in colon and prostate carcinomas, as well as in endometrial, bladder and hepatic tumors, and 30% of breast cancers. 10523833 Human
ceacam1 colon tumor We have shown in a mouse colon tumor model that CEACAM1 with a long cytoplasmic domain inhibited the development of tumors whereas a splice variant lacking the cytoplasmic domain did not. 10523833 Mouse
ceacam1 tumors We have shown in a mouse colon tumor model that CEACAM1 with a long cytoplasmic domain inhibited the development of tumors whereas a splice variant lacking the cytoplasmic domain did not. 10523833 Mouse
ceacam1 tumor In this study, we define the subregions of the long cytoplasmic domain participating in the tumor inhibition phenotype of CEACAM1. 10523833 NA
ceacam1 tumor Substitution or deletion of residues in the C-terminal region of the CEACAM1 cytoplasmic domain also led to reversal of tumor cell growth inhibition. 10523833 Mouse
ceacam1 tumor Furthermore, removal of the N-terminal domain of CEACAM1, essential for intercellular adhesion, did not impair the tumor inhibitory effect. 10523833 Mouse
bgp carcinomas Expression of four CEA family antigens (CEA, NCA, BGP and CGM2) in normal and cancerous gastric epithelial cells: up-regulation of BGP and CGM2 in carcinomas. 9533775 Human
bgp colorectal adenocarcinomas Expression of BGP and CGM2 has recently been demonstrated to be down-regulated in colorectal adenocarcinomas. 9533775 Human
bgp carcinomas The transcripts of the CEA, NCA and BGP genes evaluated by reverse transcription-polymerase chain reaction were detectable at various levels in all the gastric adenocarcinoma cell lines tested, while CGM2 mRNA was detectable in the cell lines of poorly di 9533775 Human
bgp gastric adenocarcinoma The transcripts of the CEA, NCA and BGP genes evaluated by reverse transcription-polymerase chain reaction were detectable at various levels in all the gastric adenocarcinoma cell lines tested, while CGM2 mRNA was detectable in the cell lines of poorly di 9533775 Human
bgp gastric adenocarcinomas In contrast to previous findings on normal and cancerous colonic tissues, the transcripts of CGM2 were totally undetectable and those of BGP were recognized only marginally, if at all, in normal gastric mucosa, while both messages were detected at signifi 9533775 Human
cd66a endometrial cancer Dysregulated expression of CD66a (BGP, C-CAM), an adhesion molecule of the CEA family, in endometrial cancer. 9626043 Human
bgp endometrial cancer Dysregulated expression of CD66a (BGP, C-CAM), an adhesion molecule of the CEA family, in endometrial cancer. 9626043 Human
cd66a breast cancers CD66a (BGP, C-CAM) is an adhesion molecule of the carcinoembryonic antigen family that has been shown to be down-regulated in colorectal, prostate, and breast cancers. 9626043 Human
bgp breast cancers CD66a (BGP, C-CAM) is an adhesion molecule of the carcinoembryonic antigen family that has been shown to be down-regulated in colorectal, prostate, and breast cancers. 9626043 Human
cd66a endometrial carcinomas In conclusion, CD66a protein expression is dysregulated in endometrial carcinomas, showing reduction or loss of expression with increasing malignancy grade and a change from the apical to a membranous localization. 9626043 Human
ceacam1 liver cancer The epithelial cell adhesion molecule CEACAM1 (carcinoembryonic antigen cell adhesion molecule-1) is down-regulated in colon, prostate, breast, and liver cancer. 14522961 Human
ceacam-1 cancer PURPOSE: Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) has recently been implicated in cancer development and progression. 12796394 Human
ceacam-1 non-small cell lung cancer This study was performed to assess whether CEACAM-1 expression in primary tumors is correlated to long-term survival in patients with operable non-small cell lung cancer (NSCLC). 12796394 NA
ceacam-1 tumors In contrast, 73 tumors (50.4%) showed between 1 and 66% CEACAM-1 positive tumor cells, and 72 tumors (49.6%) exhibited even a higher percentage of positive tumor cells. 12796394 Human
ceacam-1 tumor In contrast, 73 tumors (50.4%) showed between 1 and 66% CEACAM-1 positive tumor cells, and 72 tumors (49.6%) exhibited even a higher percentage of positive tumor cells. 12796394 Human
ceacam-1 adenocarcinomas A high CEACAM-1 expression rate (i.e., >/=66% positive tumor cells) was more frequent in adenocarcinomas than in squamous cell carcinomas (61.9 versus 35.7%, respectively). 12796394 Human
ceacam-1 squamous-cell carcinomas A high CEACAM-1 expression rate (i.e., >/=66% positive tumor cells) was more frequent in adenocarcinomas than in squamous cell carcinomas (61.9 versus 35.7%, respectively). 12796394 Human
ceacam-1 tumor A high CEACAM-1 expression rate (i.e., >/=66% positive tumor cells) was more frequent in adenocarcinomas than in squamous cell carcinomas (61.9 versus 35.7%, respectively). 12796394 Human
ceacam-1 tumor CONCLUSIONS: The absence of CEACAM-1 in normal lung tissue and its expression in tumor cells argues against a tumor-suppressive role of CEACAM-1 in NSCLC. 12796394 Human
ceacam-1 lung cancer The correlation between elevated CEACAM-1 expression and an unfavorable prognosis indicates rather that CEACAM-1 might promote lung cancer progression. 12796394 Human
bgp hepatocellular carcinoma To understand the molecular basis for coronavirus cross-species transfer into human cell lines, the replication of MHV-H2 was studied in hepatocellular carcinoma (HepG2) cells which expressed high levels of the human homologue of the normal murine recepto 9782263 Human
cd66 acute myeloid leukaemia Notably, CD14/CD66 co-expression patterns were related to disease categories; e.g. in chronic myelomonocytic leukaemia and acute myeloid leukaemia following a dysplastic phase the co-expression displayed two subsets in peripheral blood, low-avidity CD14 a 9855250 Human
cd66 chronic myelomonocytic leukaemia Notably, CD14/CD66 co-expression patterns were related to disease categories; e.g. in chronic myelomonocytic leukaemia and acute myeloid leukaemia following a dysplastic phase the co-expression displayed two subsets in peripheral blood, low-avidity CD14 a 9855250 Human
cd66 secondary acute myeloid leukemias In conclusion, abnormal CD14/CD66 co-expression might be a valuable parameter in defining asynchronous myelopoiesis in malignant myeloid disorders, especially myeloproliferative disorders and secondary acute myeloid leukemias. 9855250 Human
bgp colon cancer Since BGP is down regulated in colon cancer and in premalignant colonic adenomas, it has been of interest to study its expression in other tumors. 9858884 Human
bgp colonic adenomas Since BGP is down regulated in colon cancer and in premalignant colonic adenomas, it has been of interest to study its expression in other tumors. 9858884 Human
bgp breast cancer Using immunohistochemistry with a BGP specific antibody, and mRNA analysis by in situ hybridization, RNase protection, and RT-PCR, we show here that BGP is expressed to the same extent in both normal and malignant breast, demonstrating that BGP is not dow 9858884 Human
bgp invasive carcinoma In normal breast, BGP expression is confined to the apical surface of ductal and lobular epithelial cells, while in invasive carcinoma of the breast, BGP is expressed throughout the cytoplasm. 9858884 Human
bgp colon cancer Since recent studies by Turbide et al (Cancer Res 57: 2781-2788, 1997) have shown that the ratio of murine BGP isoforms may affect tumor suppression in colonic cancer, it is proposed here that the isoform difference between human breast and colon may acco 9858884 Human
bgp cancer Since recent studies by Turbide et al (Cancer Res 57: 2781-2788, 1997) have shown that the ratio of murine BGP isoforms may affect tumor suppression in colonic cancer, it is proposed here that the isoform difference between human breast and colon may acco 9858884 Human
bgp colonic cancer Since recent studies by Turbide et al (Cancer Res 57: 2781-2788, 1997) have shown that the ratio of murine BGP isoforms may affect tumor suppression in colonic cancer, it is proposed here that the isoform difference between human breast and colon may acco 9858884 Human
bgp tumor Since recent studies by Turbide et al (Cancer Res 57: 2781-2788, 1997) have shown that the ratio of murine BGP isoforms may affect tumor suppression in colonic cancer, it is proposed here that the isoform difference between human breast and colon may acco 9858884 Human
bgp colon cancer Cell surface levels of CEA and the CEA family member nonspecific crossreacting antigen (NCA), both overexpressed in colon cancer, were higher in LS-174T than in SW-1222 cells, whereas family member biliary glycoprotein (BGP), downregulated in colon carcin 9028835 Human
bgp colon carcinoma Cell surface levels of CEA and the CEA family member nonspecific crossreacting antigen (NCA), both overexpressed in colon cancer, were higher in LS-174T than in SW-1222 cells, whereas family member biliary glycoprotein (BGP), downregulated in colon carcin 9028835 Human
bgp hepatocellular carcinomas We have earlier demonstrated that BGP mRNA is expressed in hepatocellular carcinomas (HCCs) and the adjacent non-cancerous regions, neither of which express CEA and NCA mRNA. 9036863 Human
bgp hepatocellular carcinoma The BGP transfectants of cultured hepatocellular carcinoma cHc-4 cells showed Ca2+-dependent cell aggregation, which was partially inhibited by modulating BGP on the cell surface with MAb TS135. 9036863 Human
bgp prostatic tumor Moreover, we and others demonstrated that Bgp can inhibit colonic and prostatic tumor cell growth in vivo, through a mechanism which depends on sequences present in its cytoplasmic domain. 9047385 Human
bgp colon carcinoma We showed that tyrosine phosphorylated Bgp, expressed in mouse colon carcinoma CT51 cells, could reversibly associate with protein tyrosine phosphatase SHP-1. 9047385 Human
bgp colorectal tumors Only low CGM2 and BGP mRNA levels were seen in colorectal tumors. 9135022 Human
bgp tumor The CGM2 expression pattern along with its sequence homology to BGP suggests a similar tumor suppressor function for CGM2. 9135022 Human
cd66a colorectal adenomas Expression of CD66a (human C-CAM) and other members of the carcinoembryonic antigen gene family of adhesion molecules in human colorectal adenomas. 9192807 Human
cd66a colorectal cancer Among the members of the carcinoembryonic antigen (CEA) family, CD66a (human C-CAM) and CGM2 (CEA gene family member 2) mRNAs are frequently down-regulated in colorectal cancer. 9192807 Human
cd66a tumor In animal models, the rodent homologues of CD66a have been shown to act as tumor suppressors, suggesting an important role in carcinogenesis. 9192807 Mouse
cd66a colorectal adenomas Here we investigate the mRNAs of CD66a, CGM2, and NCA in 22 human colorectal adenomas and the respective normal mucosa specimens by Northern blots. 9192807 Human
cd66a tumors Complete or near-complete losses of the CD66a 3.9-kb mRNA and the CGM2 message were found in 13 of 22 and 15 of 22 of the tumors, respectively. 9192807 Human
bgp tumor Rodent biliary glycoprotein (Bgp), also known as C-CAM, has recently been shown to function as a tumor suppressor in colon, prostate, and bladder cancers. 9205090 Mouse
bgp bladder cancers Rodent biliary glycoprotein (Bgp), also known as C-CAM, has recently been shown to function as a tumor suppressor in colon, prostate, and bladder cancers. 9205090 Mouse
bgp tumor To mimic the in vivo situation, we have generated double transfectant cell lines expressing the longer and shorter Bgp isoforms coordinately in tumorigenic CT51 mouse colonic carcinoma cells and demonstrated that the longer Bgp isoform exhibits a dominant 9205090 Mouse
bgp colonic carcinoma To mimic the in vivo situation, we have generated double transfectant cell lines expressing the longer and shorter Bgp isoforms coordinately in tumorigenic CT51 mouse colonic carcinoma cells and demonstrated that the longer Bgp isoform exhibits a dominant 9205090 Mouse
bgp tumor Unexpectedly, significant overexpression of the longer Bgp isoform alone led to reversal of the tumor inhibition phenotype. 9205090 Mouse
bgp tumor These results, therefore, suggest that there may be a limiting threshold of Bgp expression or Bgp-associating proteins mediating the tumor inhibition phenotype. 9205090 Mouse
cd66a tumor There is evidence that aberrant expression or loss of CD66a in tumor tissue is of biological significance. 9212821 Human
cd66a breast carcinoma No data about its expression in breast carcinoma cells and only sparse information about the expression of CD66a in normal breast are available thus far. 9212821 Human
cd66a invasive carcinomas In this study we used monoclonal antibodies to analyze the expression of CD66a and CEA in normal tissue, benign lesions, and in noninvasive and invasive carcinomas of the mammary gland. 9212821 NA
cd66a invasive carcinomas However, the apical expression of CD66a disappeared with the development of the malignant phenotype in noninvasive and invasive carcinomas, and changed gradually from low- to high-grade noninvasive carcinomas into a predominant uniform membrane staining a 9212821 Human
cd66a carcinomas However, the apical expression of CD66a disappeared with the development of the malignant phenotype in noninvasive and invasive carcinomas, and changed gradually from low- to high-grade noninvasive carcinomas into a predominant uniform membrane staining a 9212821 Human
cd66a invasive carcinomas The native apical CD66a staining was partially preserved in some highly differentiated invasive carcinomas with a better prognosis, such as tubular and papillary carcinomas. 9212821 Human
cd66a papillary carcinomas The native apical CD66a staining was partially preserved in some highly differentiated invasive carcinomas with a better prognosis, such as tubular and papillary carcinomas. 9212821 Human
cd66a colorectal carcinomas Dysregulation of carcinoembryonic antigen group members CGM2, CD66a (biliary glycoprotein), and nonspecific cross-reacting antigen in colorectal carcinomas. 9250164 Human
cd66a colorectal carcinomas We investigated a series of 11 colorectal carcinomas by Northern blot and isotopic in situ hybridization (ISH), demonstrating underexpression of CD66a and CGM2 in the majority of the carcinomas as compared with the normal mucosa, whereas NCA was overexpre 9250164 Human
cd66a carcinomas We investigated a series of 11 colorectal carcinomas by Northern blot and isotopic in situ hybridization (ISH), demonstrating underexpression of CD66a and CGM2 in the majority of the carcinomas as compared with the normal mucosa, whereas NCA was overexpre 9250164 Human
cd66a carcinomas ISH for CD66a and CGM2 mRNA revealed that large areas of the carcinomas remained without or with only faint hybridization signals. 9250164 Human
cd66a carcinoma However, in every carcinoma, at least some positive foci were observed, indicating remaining cell populations that actively transcribe CD66a and CGM2. 9250164 Human
bgp neoplasms OBJECTIVE: The aim of this study was to examine the expression of glycoproteins of the CEA family, that is, CEA-180, nonspecific cross-reacting antigens (NCAs), and biliary glycoprotein (BGP), in sebaceous glands and in neoplasms with sebaceous differenti 8632066 NA
bgp hyperplasias METHODS: Normal adult and fetal skin, hyperplasias, hamartomas, and neoplasms with sebaceous or follicular differentiation were stained immunohistochemically with a panel of polyclonal and monoclonal antibodies highly specific for CEA-180, NCAs, and BGP. 8632066 NA
bgp neoplasms METHODS: Normal adult and fetal skin, hyperplasias, hamartomas, and neoplasms with sebaceous or follicular differentiation were stained immunohistochemically with a panel of polyclonal and monoclonal antibodies highly specific for CEA-180, NCAs, and BGP. 8632066 NA
bgp cancer These "new" members are glycophosphatidylinositol linked to the external cell membrane and are up-regulated in cancer, unlike members present in both rodents and primates, i.e., biliary glycoprotein (BGP), which are transmembrane linked and down 8732675 Human
bgp cancer Finally, the myogenic differentiation block demonstrated for the ectopic expression of CEA in myoblasts was also observed for NCA but not for BGP, which is consistent with the changes in expression seen in cancer. 8732675 Human
bgp neoplasms Neoplasms with signs of apocrine secretion showed a preferential immunoreactivity for NCA-90 and BGP. 8720980 Human
bgp tumors Biliary glycoprotein (BGP), also known as C-CAM-1, has been shown to be down-regulated in colon and prostate tumors. 8910434 Human
bgp colon cancer Previously, we demonstrated that BGP mRNA is up-regulated by interferon-gamma (IFN-gamma) in colon cancer cell lines (Takahashi, H., Okai, Y., Paxton, R. J., Hefta, L. J. F., and Shively, J. E. 8910434 Human
ceacam1 mammary carcinoma We show that mammary carcinoma cells (MCF7), which do not express CEACAM1 or form lumena when grown in Matrigel, are restored to a normal morphogenic program when transfected with CEACAM1-4S, the short cytoplasmic isoform of CEACAM1 that predominates in b 12522268 Human
cd66 breast cancer No PLF-induced alterations of protectin, CD66 antigen and HLA class I antigen were found on the MDA-MB-468 breast cancer cell line. 7542560 Human
bgp cancer In contrast to CEA, whose overexpression has been correlated with cancer progression, the human and mouse Bgp proteins are generally down-regulated upon tumor formation. 7628460 Human
bgp tumor In contrast to CEA, whose overexpression has been correlated with cancer progression, the human and mouse Bgp proteins are generally down-regulated upon tumor formation. 7628460 Human
cd66a colorectal carcinomas Association of pp60c-src with biliary glycoprotein (CD66a), an adhesion molecule of the carcinoembryonic antigen family downregulated in colorectal carcinomas. 7478590 Human
cd66a colorectal cancer The down-regulation of CD66a in about 80% of colorectal carcinomas may contribute to a dysregulation of pp60c-src in colorectal cancer. 7478590 Human
cd66a colorectal carcinomas The down-regulation of CD66a in about 80% of colorectal carcinomas may contribute to a dysregulation of pp60c-src in colorectal cancer. 7478590 Human
bgp liver carcinomas In previous studies, BGP expression has been reported to be generally downregulated in colon and liver carcinomas of human, rat and mouse origins. 8570189 Human
bgp1 colonic carcinoma We now demonstrate that introduction of murine Bgp1 cDNA isoforms into a mouse colonic carcinoma cell line, negative for endogenous Bgpl expression, significantly alters the growth properties of these cells. 8570189 Mouse
bgp1 tumors Furthermore, tumor formation was inhibited by 80% when cells bearing a full-length Bgp1 isoform were injected into BALB/c syngeneic mice, while cells expressing a Bgp1 isoform lacking most of the intracytoplasmic domain produced tumors as readily as the p 8570189 Mouse
bgp1 tumor Furthermore, tumor formation was inhibited by 80% when cells bearing a full-length Bgp1 isoform were injected into BALB/c syngeneic mice, while cells expressing a Bgp1 isoform lacking most of the intracytoplasmic domain produced tumors as readily as the p 8570189 Mouse
bgpi liver cell tumors Immunohistochemistry of CEA and BGPI, however, appeared to be of help in differentiating between primary and secondary liver tumors as follows: CEA is consistently absent in liver cell tumors, while a bile canalicular staining pattern was seen in 80% of H 2430547 Human
bgpi liver tumors Immunohistochemistry of CEA and BGPI, however, appeared to be of help in differentiating between primary and secondary liver tumors as follows: CEA is consistently absent in liver cell tumors, while a bile canalicular staining pattern was seen in 80% of H 2430547 Human
bgp tumor Antibody dependent lymphocyte (K cell) mediated lysis of tumor cells in vitro was used to assay for cell surface associated carcinoembryonic antigen (CEA) and two CEA-related normal tissue components, "normal glycoprotein" (NGP) and biliary glyc 873641 Human
bgp hepatocellular carcinoma Among large polygonal cell carcinomas (hepatocellular carcinoma, renal cell carcinoma, melanoma, and adrenal carcinoma), only hepatomas stained positively, showing a distinctive canalicular staining pattern with the B18 (BGP epitope) (55%) and polyclonal 1695478 Human
bgp melanoma Among large polygonal cell carcinomas (hepatocellular carcinoma, renal cell carcinoma, melanoma, and adrenal carcinoma), only hepatomas stained positively, showing a distinctive canalicular staining pattern with the B18 (BGP epitope) (55%) and polyclonal 1695478 Human
bgp carcinoma Among large polygonal cell carcinomas (hepatocellular carcinoma, renal cell carcinoma, melanoma, and adrenal carcinoma), only hepatomas stained positively, showing a distinctive canalicular staining pattern with the B18 (BGP epitope) (55%) and polyclonal 1695478 Human
bgp renal-cell carcinoma Among large polygonal cell carcinomas (hepatocellular carcinoma, renal cell carcinoma, melanoma, and adrenal carcinoma), only hepatomas stained positively, showing a distinctive canalicular staining pattern with the B18 (BGP epitope) (55%) and polyclonal 1695478 Human
bgp epithelial tumors The authors conclude that CEA immunostaining may assist in identifying the histogenesis of epithelial tumors in several morphologic categories; that differential reactivities of the CEA monoclonal antibody panel exceed those of the polyclonal antibody; an 1695478 Human
ceacam1 colorectal cancers (crc) PURPOSE: CEACAM6, CEACAM1, and human carcinoembryonic antigen (CEA) are coexpressed in normal colorectal epithelia, but show deregulated expression in colorectal cancers (CRC). 14512395 Human
bgpi gastrointestinal carcinomas Both chimeric Fab fragments exhibited strong immunohistochemical reactivity with various gastrointestinal carcinomas and no reactivity with CEA-related antigens, such as NCA (nonspecific cross-reacting antigen) or BGPI (biliary glycoprotein I). 8188529 Human
bgp metastatic cancer The mRNA expression of BGP gene was investigated in specimens of primary and metastatic cancer tissues from 15 patients with primary lung cancer (six squamous cell carcinomas, five adenocarcinomas, and four small cell carcinomas). 8049082 Human
bgp small-cell carcinomas The mRNA expression of BGP gene was investigated in specimens of primary and metastatic cancer tissues from 15 patients with primary lung cancer (six squamous cell carcinomas, five adenocarcinomas, and four small cell carcinomas). 8049082 Human
bgp squamous-cell carcinomas The mRNA expression of BGP gene was investigated in specimens of primary and metastatic cancer tissues from 15 patients with primary lung cancer (six squamous cell carcinomas, five adenocarcinomas, and four small cell carcinomas). 8049082 Human
bgp primary lung cancer The mRNA expression of BGP gene was investigated in specimens of primary and metastatic cancer tissues from 15 patients with primary lung cancer (six squamous cell carcinomas, five adenocarcinomas, and four small cell carcinomas). 8049082 Human
bgp adenocarcinomas The mRNA expression of BGP gene was investigated in specimens of primary and metastatic cancer tissues from 15 patients with primary lung cancer (six squamous cell carcinomas, five adenocarcinomas, and four small cell carcinomas). 8049082 Human
bgp squamous-cell carcinoma BGP mRNA expression was increased in carcinomatous tissues of the primary site, especially in squamous cell carcinoma, but was not detected in adjacent normal tissues by Northern blot analysis or in situ hybridization. 8049082 Human
bgp squamous-cell carcinoma Interestingly, BGP mRNA expression was apparently decreased in metastatic lesions compared with the primary site in the six individuals with squamous cell carcinoma. 8049082 Human
bgp squamous-cell carcinoma These results suggest that the reduction of BGP expression may play an important role in the process of metastasis through decreasing adhesive interactions with surrounding cells, especially in squamous cell carcinoma. 8049082 Human
bgp metastasis These results suggest that the reduction of BGP expression may play an important role in the process of metastasis through decreasing adhesive interactions with surrounding cells, especially in squamous cell carcinoma. 8049082 Human
bgp human colorectal carcinomas Since the loss or reduced expression of BGP is associated with human colorectal carcinomas, the elements in its upstream regulatory region were analyzed. 8055923 Human
cd66 childhood acute lymphoblastic leukemias Expression of the CEA gene family members NCA-50/90 and NCA-160 (CD66) in childhood acute lymphoblastic leukemias (ALLs) and in cell lines of B-cell origin. 7808000 Human
cd66 human breast carcinoma Expression and alterations of CD66 antigen by interferon-gamma in human breast carcinoma cell lines. 7872669 Human
cd66 human breast carcinoma Monoclonal antibodies of the CD66/67 panel from the 5th Workshop on Leukocyte Antigens bound (as determined by flow cytometry) to the cell surface of human breast carcinoma cell lines BT-20 and MDA-MB-468. 7872669 Human
cd66 breast carcinoma The molecular weight of antigenic polypeptides recognized by the CD66 monoclonal antibody F34-187 differed between the two examined breast carcinoma lines as follows: 50kDa, 95 kDa and 130 kDa polypeptides were expressed on both BT-20 and MCF-7 cell lines 7872669 Human
cd66 breast carcinoma Different alterations of CD66 antigenic polypeptides recognized by F34-187 monoclonal antibody, induced by interferon-gamma and indentified by immunoblotting, were found on BT-20, MCF-7 and MDA-MB-468 breast carcinoma cell lines. 7872669 Human
bgp metastases Carcinoembryonic antigen (CEA) positivity of bile canaliculi by cross-reaction with biliary glycoprotein I (BGP I) made possible the differentiation of HCC from metastases. 7880969 Human
ceacam1 breast cancer Down-regulation of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) tumor suppressor gene expression is common in several malignancies including prostate, colon, and breast cancer. 15126343 Human
ceacam1 prostate cancer Here, we report that down-regulation of CEACAM1 expression in prostate cancer cells occurs primarily at the transcriptional level and is mediated by Sp2, a member of the Sp family of transcription factors. 15126343 Human
ceacam1 human prostate cancer In human prostate cancer specimens, Sp2 expression is high in prostate cancer cells but low in normal prostate epithelial cells and is inversely correlated with CEACAM1 expression. 15126343 Human
ceacam1 prostate cancer In human prostate cancer specimens, Sp2 expression is high in prostate cancer cells but low in normal prostate epithelial cells and is inversely correlated with CEACAM1 expression. 15126343 Human
ceacam1 prostate cancer Our studies show that transcriptional repression by Sp2 represents one mechanism by which CEACAM1 tumor suppressor gene is down-regulated in prostate cancer. 15126343 Human
cd66 lymphoma However, the reactions of the two antibodies differed on kidney, liver and pancreas, and in cases of myeloma, Waldenström's macroglobulinaemia and lymphoma, indicating that By114 represents a new CD66 sub-specificity. 8435334 Human
cd66 myeloma However, the reactions of the two antibodies differed on kidney, liver and pancreas, and in cases of myeloma, Waldenström's macroglobulinaemia and lymphoma, indicating that By114 represents a new CD66 sub-specificity. 8435334 Human
bgp ovarian mucinous adenocarcinomas In ovarian mucinous adenocarcinomas, we always found co-expression of CEA and NCA transcripts, and occasionally BGP mRNA. 7690349 Human
bgp cervical carcinomas CEA, NCA and BGP transcripts were present in endometrial carcinomas of the uterus and cervical carcinomas, whereas uterine leiomyomas were completely negative. 7690349 Human
bgp endometrial carcinomas CEA, NCA and BGP transcripts were present in endometrial carcinomas of the uterus and cervical carcinomas, whereas uterine leiomyomas were completely negative. 7690349 Human
bgp carcinoma Since human carcinoembryonic antigen is overexpressed in gastrointestinal tumors, we have investigated the expression of mouse Bgp in primary tumors and carcinoma cell lines. 8402684 Human
bgp gastrointestinal tumors Since human carcinoembryonic antigen is overexpressed in gastrointestinal tumors, we have investigated the expression of mouse Bgp in primary tumors and carcinoma cell lines. 8402684 Human
bgp tumors Our results demonstrate that the expression of the major mouse Bgp isoforms is down-regulated in tumors at the transcriptional and the posttranscriptional levels. 8402684 Mouse
bgp tumors This decrease in expression is corroborated by immunostaining of primary colonic tumors with anti-mouse Bgp antibodies. 8402684 Mouse
bgp colorectal carcinoma Since BGP is a major human CAM, the expression of BGP was studied in 21 colorectal carcinoma tissue specimens and in the respective adjacent normal mucosae. 7504281 Human
bgp tumors Relative to cytokeratin 18 expression, the expression of BGP was reduced to < or = 0.1 in half of the tumors and to < or = 0.4 in > 80% of the tumors. 7504281 Human
bgp chronic myelogenous leukaemia Here we show that BGPa and BGPb are phosphorylated in the chronic myelogenous leukaemia cell line KG-1, which constitutively expresses several BGP isoforms, and Chinese hamster LR-73 cells transfected with the cDNAs encoding BGPa and BGPb. 1371937 Human
bgp lung cancers Carcinoembryonic antigen (CEA), a tumor marker for lung cancers of small cell (SCLC) and non-small cell (NSCLC) types, belongs in a multigene family which includes non-specific cross-reacting antigen (NCA) and biliary glycoprotein 1 (BGP). 1330929 Human
bgp tumor Carcinoembryonic antigen (CEA), a tumor marker for lung cancers of small cell (SCLC) and non-small cell (NSCLC) types, belongs in a multigene family which includes non-specific cross-reacting antigen (NCA) and biliary glycoprotein 1 (BGP). 1330929 Human
bgp colon carcinoma Three Carcinoembryonic Antigen (CEA) gene family members: CEA, Non-specific cross-reactive antigen 50/90 (NCA) and biliary glycoprotein (BGP) were expressed in the colon carcinoma cell lines LS174T and HT29. 1815506 Human
bgp tumor CEA and NCA50/90, but not BGP, were linked to the cell membrane via glycosyl phosphatidyl inositol and could be released from the intact tumor cells by glycosyl phosphatidyl inositol-specific phospholipase C. CEA on isolated membranes and in cell lysates, 1815506 Human
bgp hepatomas Among large polygonal cell carcinomas (hepatocellular carcinoma, renal cell carcinoma, melanoma, and adrenal carcinoma), only hepatomas stained positively, showing a distinctive canalicular staining pattern with the B18 (BGP epitope) (55%) and polyclonal 1695478 Human
bgp adrenal carcinoma Among large polygonal cell carcinomas (hepatocellular carcinoma, renal cell carcinoma, melanoma, and adrenal carcinoma), only hepatomas stained positively, showing a distinctive canalicular staining pattern with the B18 (BGP epitope) (55%) and polyclonal 1695478 Human
bgp bone metastasis [Clinical evaluation of bone turnover in patients with bone metastasis of various cancer of urogenital tract] To study the bone turnover in patients with bone metastasis from cancers of the kidney, bladder, prostate and other organs, Ca metabolism, vitami 2232410 Human
bgp nsclc Carcinoembryonic antigen (CEA), a tumor marker for lung cancers of small cell (SCLC) and non-small cell (NSCLC) types, belongs in a multigene family which includes non-specific cross-reacting antigen (NCA) and biliary glycoprotein 1 (BGP). 1330929 Human
bgp primary tumors Since human carcinoembryonic antigen is overexpressed in gastrointestinal tumors, we have investigated the expression of mouse Bgp in primary tumors and carcinoma cell lines. 8402684 Human
bgp colonic tumors This decrease in expression is corroborated by immunostaining of primary colonic tumors with anti-mouse Bgp antibodies. 8402684 Mouse
bgp bone tumors These observations indicate that BGP synthesis is a late event in osteoblastic development and that antibodies generated against the propeptide sequence are a potentially powerful tool in the analysis of bone tumors and evaluation of osteoblastic differen 8086856 Human
bgp hcc Carcinoembryonic antigen (CEA) positivity of bile canaliculi by cross-reaction with biliary glycoprotein I (BGP I) made possible the differentiation of HCC from metastases. 7880969 Human
bgp hamartomas METHODS: Normal adult and fetal skin, hyperplasias, hamartomas, and neoplasms with sebaceous or follicular differentiation were stained immunohistochemically with a panel of polyclonal and monoclonal antibodies highly specific for CEA-180, NCAs, and BGP. 8632066 NA
bgp prostate tumors Biliary glycoprotein (BGP), also known as C-CAM-1, has been shown to be down-regulated in colon and prostate tumors. 8910434 Human
bgp other tumors Since BGP is down regulated in colon cancer and in premalignant colonic adenomas, it has been of interest to study its expression in other tumors. 9858884 Human
bgp invasive carcinoma of the breast In normal breast, BGP expression is confined to the apical surface of ductal and lobular epithelial cells, while in invasive carcinoma of the breast, BGP is expressed throughout the cytoplasm. 9858884 Human
bgpi hcc Immunohistochemistry of CEA and BGPI, however, appeared to be of help in differentiating between primary and secondary liver tumors as follows: CEA is consistently absent in liver cell tumors, while a bile canalicular staining pattern was seen in 80% of H 2430547 Human
biliary glycoprotein colonic carcinoma Identification of membrane antigens in granulocytes and colonic carcinoma cells by a monoclonal antibody specific for biliary glycoprotein, a member of the carcinoembryonic antigen family. 1998947 Human
biliary glycoprotein colon carcinoma Three Carcinoembryonic Antigen (CEA) gene family members: CEA, Non-specific cross-reactive antigen 50/90 (NCA) and biliary glycoprotein (BGP) were expressed in the colon carcinoma cell lines LS174T and HT29. 1815506 Human
biliary glycoprotein nsclc Carcinoembryonic antigen (CEA), a tumor marker for lung cancers of small cell (SCLC) and non-small cell (NSCLC) types, belongs in a multigene family which includes non-specific cross-reacting antigen (NCA) and biliary glycoprotein 1 (BGP). 1330929 Human
biliary glycoprotein lung cancers Carcinoembryonic antigen (CEA), a tumor marker for lung cancers of small cell (SCLC) and non-small cell (NSCLC) types, belongs in a multigene family which includes non-specific cross-reacting antigen (NCA) and biliary glycoprotein 1 (BGP). 1330929 Human
biliary glycoprotein colorectal carcinomas Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas. 7504281 Human
biliary glycoprotein biliary cancer All samples of bile from the patients with biliary cancer showed three bands that corresponded to CEA, nonspecific crossreacting antigen, and biliary glycoprotein 1, respectively. 8160902 Human
biliary glycoprotein gastrointestinal carcinomas Both chimeric Fab fragments exhibited strong immunohistochemical reactivity with various gastrointestinal carcinomas and no reactivity with CEA-related antigens, such as NCA (nonspecific cross-reacting antigen) or BGPI (biliary glycoprotein I). 8188529 Human
biliary glycoprotein squamous-cell carcinoma Biliary glycoprotein mRNA expression is increased in primary lung cancer, especially in squamous cell carcinoma. 8049082 Human
biliary glycoprotein primary lung cancer Biliary glycoprotein mRNA expression is increased in primary lung cancer, especially in squamous cell carcinoma. 8049082 Human
biliary glycoprotein colorectal carcinomas Transcriptional control of the human biliary glycoprotein gene, a CEA gene family member down-regulated in colorectal carcinomas. 8055923 Human
biliary glycoprotein hcc Carcinoembryonic antigen (CEA) positivity of bile canaliculi by cross-reaction with biliary glycoprotein I (BGP I) made possible the differentiation of HCC from metastases. 7880969 Human
biliary glycoprotein metastases Carcinoembryonic antigen (CEA) positivity of bile canaliculi by cross-reaction with biliary glycoprotein I (BGP I) made possible the differentiation of HCC from metastases. 7880969 Human
biliary glycoprotein colorectal carcinomas Association of pp60c-src with biliary glycoprotein (CD66a), an adhesion molecule of the carcinoembryonic antigen family downregulated in colorectal carcinomas. 7478590 Human
biliary glycoprotein colonic tumor Inhibition of colonic tumor cell growth by biliary glycoprotein. 8570189 Mouse
biliary glycoprotein colonic tumor There results indicate that a biliary glycoprotein isoform is involved in negative regulation of colonic tumor cell growth, by a process which requires its intracytoplasmic domain. 8570189 Mouse
biliary glycoprotein neoplasms OBJECTIVE: The aim of this study was to examine the expression of glycoproteins of the CEA family, that is, CEA-180, nonspecific cross-reacting antigens (NCAs), and biliary glycoprotein (BGP), in sebaceous glands and in neoplasms with sebaceous differenti 8632066 NA
biliary glycoprotein cancer These "new" members are glycophosphatidylinositol linked to the external cell membrane and are up-regulated in cancer, unlike members present in both rodents and primates, i.e., biliary glycoprotein (BGP), which are transmembrane linked and down 8732675 Human
biliary glycoprotein prostate tumors Biliary glycoprotein (BGP), also known as C-CAM-1, has been shown to be down-regulated in colon and prostate tumors. 8910434 Human
biliary glycoprotein colon cancer Cell surface levels of CEA and the CEA family member nonspecific crossreacting antigen (NCA), both overexpressed in colon cancer, were higher in LS-174T than in SW-1222 cells, whereas family member biliary glycoprotein (BGP), downregulated in colon carcin 9028835 Human
biliary glycoprotein colon carcinoma Cell surface levels of CEA and the CEA family member nonspecific crossreacting antigen (NCA), both overexpressed in colon cancer, were higher in LS-174T than in SW-1222 cells, whereas family member biliary glycoprotein (BGP), downregulated in colon carcin 9028835 Human
biliary glycoprotein hepatocellular carcinomas Decreased expression of biliary glycoprotein in hepatocellular carcinomas. 9036863 Human
biliary glycoprotein tumors Cell-surface NCA showed even greater overexpression (up to 70-told) in dedifferentiated tumors, whereas total-cell biliary glycoprotein showed approximately 2-fold lower levels than was normal in more differentiated tumors and approximately 2-fold higher 9166289 Human
biliary glycoprotein colonic tumor Optimal ratios of biliary glycoprotein isoforms required for inhibition of colonic tumor cell growth. 9205090 Mouse
biliary glycoprotein tumor Rodent biliary glycoprotein (Bgp), also known as C-CAM, has recently been shown to function as a tumor suppressor in colon, prostate, and bladder cancers. 9205090 Mouse
biliary glycoprotein bladder cancers Rodent biliary glycoprotein (Bgp), also known as C-CAM, has recently been shown to function as a tumor suppressor in colon, prostate, and bladder cancers. 9205090 Mouse
biliary glycoprotein colorectal carcinomas Dysregulation of carcinoembryonic antigen group members CGM2, CD66a (biliary glycoprotein), and nonspecific cross-reacting antigen in colorectal carcinomas. 9250164 Human
biliary glycoprotein hepatocellular carcinoma To understand the molecular basis for coronavirus cross-species transfer into human cell lines, the replication of MHV-H2 was studied in hepatocellular carcinoma (HepG2) cells which expressed high levels of the human homologue of the normal murine recepto 9782263 Human
biliary glycoprotein tumor Antibody dependent lymphocyte (K cell) mediated lysis of tumor cells in vitro was used to assay for cell surface associated carcinoembryonic antigen (CEA) and two CEA-related normal tissue components, "normal glycoprotein" (NGP) and biliary glyc 873641 Human
biliary glycoprotein cancers Human carcinoembryonic antigen (CEA), a widely used tumor marker, and CEACAM6 [formerly nonspecific cross-reacting antigen (NCA)] are up-regulated in many types of human cancers, whereas family member CEACAM1 [formerly biliary glycoprotein (BGP)] is usual 10910050 Human
biliary glycoprotein tumor Biliary glycoprotein (Bgp, C-CAM, or CD66a) is an immunoglobulin-like cell adhesion molecule and functions as a tumor suppressor protein. 9867848 Human
biliary glycoprotein breast cancers CEACAM1 (also known as biliary glycoprotein, C-CAM or CD66a) is a cell adhesion molecule of the immunoglobulin family behaving as a tumor inhibitory protein in colon, prostate, liver, endometrial and breast cancers. 11313949 Human
biliary glycoprotein tumor PURPOSE: Biliary glycoprotein (BGP), a member of the carcinoembryonic antigen (CEA) gene family, is produced by hepatocytes, and is suggested to function as a cell adhesion molecule, mouse hepatitis virus receptor, and tumor suppressor. 11480791 Human
carcinoembryonic antigen-related cell adhesion molecule 1 human tumors The carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a member of the immunoglobulin superfamily, is expressed in microvessels of proliferating tissues such as endometrium, in tissues after wounding, and in solid human tumors. 11082271 Human
carcinoembryonic antigen-related cell adhesion molecule 1 tumor Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), an Ig-like transmembrane protein, functions in cell adhesion, angiogenesis and epithelial cell morphogenesis, and has been identified as a tumor suppressor. 12108545 Human
carcinoembryonic antigen-related cell adhesion molecule 1 non-small cell lung cancer Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. 12796394 Human
carcinoembryonic antigen-related cell adhesion molecule 1 cancer PURPOSE: Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) has recently been implicated in cancer development and progression. 12796394 Human
carcinoembryonic antigen-related cell adhesion molecule 1 breast cancer Down-regulation of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) tumor suppressor gene expression is common in several malignancies including prostate, colon, and breast cancer. 15126343 Human
carcinoembryonic antigen-related cell adhesion molecule 1 human urinary bladder cancer Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. 15604255 Human
carcinoembryonic antigen-related cell adhesion molecule 1 transitional cell carcinoma in situ Here, we show that carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is expressed in umbrella cells of bladder urothelium but is down-regulated in superficial bladder cancer, such as histologic tumor stage a (pTa) and transitional cell c 15604255 Human
carcinoembryonic antigen-related cell adhesion molecule 1 tumor Here, we show that carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is expressed in umbrella cells of bladder urothelium but is down-regulated in superficial bladder cancer, such as histologic tumor stage a (pTa) and transitional cell c 15604255 Human
carcinoembryonic antigen-related cell adhesion molecule 1 superficial bladder cancer Here, we show that carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is expressed in umbrella cells of bladder urothelium but is down-regulated in superficial bladder cancer, such as histologic tumor stage a (pTa) and transitional cell c 15604255 Human
carcinoembryonic antigen-related cell adhesion molecule 1 hepatocellular carcinoma Loss of carcinoembryonic antigen-related cell adhesion molecule 1 expression is an adverse prognostic factor in hepatocellular carcinoma. 15952183 Human
carcinoembryonic antigen-related cell adhesion molecule 1 tumor BACKGROUND: Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a negative regulator of tumor cell growth, and may function as a tumor suppressor. 15952183 Human
cd66a malignancy In conclusion, CD66a protein expression is dysregulated in endometrial carcinomas, showing reduction or loss of expression with increasing malignancy grade and a change from the apical to a membranous localization. 9626043 Human
cd66a prostate tumors We have observed previously that CD66a protein expression is lost in most prostate tumors, suggesting that the down-regulation of CD66a is associated with the abnormal growth of prostate cells. 10419049 Human
ceacam-1 nsclc This study was performed to assess whether CEACAM-1 expression in primary tumors is correlated to long-term survival in patients with operable non-small cell lung cancer (NSCLC). 12796394 NA
ceacam-1 primary tumors This study was performed to assess whether CEACAM-1 expression in primary tumors is correlated to long-term survival in patients with operable non-small cell lung cancer (NSCLC). 12796394 NA
ceacam-1 nsclc CONCLUSIONS: The absence of CEACAM-1 in normal lung tissue and its expression in tumor cells argues against a tumor-suppressive role of CEACAM-1 in NSCLC. 12796394 Human
ceacam1 epithelial tumor CEACAM1 functions as an epithelial tumor suppressor and as an angiogenic growth factor. 11035932 Human
ceacam1 choriocarcinomas In choriocarcinomas, areas of weak expression could be observed along with large areas without CEACAM1 expression. 11293162 Human
ceacam1 prostate tumor CEACAM1 has cell adhesion activity and acts as a signaling molecule, and long-tail isoforms inhibit the growth of colon and prostate tumor cells in rodents. 11483763 Human
ceacam1 prostate tumor Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. 12122002 Human
ceacam1 adenocarcinomas of the lung PURPOSE: To evaluate the prognostic relevance of CEACAM1 and sialyl Lewis X expression in adenocarcinomas of the lung. 12409325 NA
ceacam1 adenocarcinomas of the lung CONCLUSION: Expression of CEACAM1 was an independent prognostic factor in our patient population and can be used to stratify patients with adenocarcinomas of the lung into low-risk and high-risk groups. 12409325 Human
ceacam1 tumors Whereas CEA is highly expressed in adenocarcinomas, CEACAM1 expression is down regulated in many tumors and its tumor-supressive function was confirmed. 12920788 Human
ceacam1 adenocarcinomas Whereas CEA is highly expressed in adenocarcinomas, CEACAM1 expression is down regulated in many tumors and its tumor-supressive function was confirmed. 12920788 Human
ceacam1 inflammatory bowel disease These results indicate that CEACAM1 isoforms are a novel class of activation-induced cell surface molecules on T cells that function in the specific regulation of Th1-mediated inflammation such as that associated with inflammatory bowel disease. 14970176 Mouse
ceacam1 seminomas CEACAM1 staining was absent in vascular endothelial cells of normal testicular tissue, but present in small blood vessels of seminomas. 14985475 Human
ceacam1 germ-cell tumours Additionally, CEACAM1 is apparently involved in the angiogenesis of germ cell tumours. 14985475 Human
ceacam1 tumours Although most invasive ductal carcinomas express CEACAM1 (21/26), the staining pattern tends to be weak and cytoplasmic in tumours with minimal lumena formation (grades 2-3), while there is membrane staining in well-differentiated tumours (grade 1). 15339048 Human
ceacam1 invasive ductal carcinomas Although most invasive ductal carcinomas express CEACAM1 (21/26), the staining pattern tends to be weak and cytoplasmic in tumours with minimal lumena formation (grades 2-3), while there is membrane staining in well-differentiated tumours (grade 1). 15339048 Human
ceacam1 tumour CEACAM1 acts as a tumour suppressor in various epithelial tumours. 15476270 Human
ceacam1 epithelial tumours CEACAM1 acts as a tumour suppressor in various epithelial tumours. 15476270 Human
ceacam1 melanoma On the other hand, de novo expression of CEACAM1 is strongly associated with reduced disease-free survival of melanoma and non-small cell lung carcinoma patients. 15476270 Human
ceacam1 non-small cell lung carcinoma On the other hand, de novo expression of CEACAM1 is strongly associated with reduced disease-free survival of melanoma and non-small cell lung carcinoma patients. 15476270 Human
ceacam1 renal adenomas Here, we describe CEACAM1 expression in normal kidney, renal adenomas and renal cell carcinomas (RCC) using a novel antibody generated by genetic immunization. 15476270 Human
ceacam1 renal cell carcinomas (rcc) Here, we describe CEACAM1 expression in normal kidney, renal adenomas and renal cell carcinomas (RCC) using a novel antibody generated by genetic immunization. 15476270 Human
ceacam1 tumour In contrast, tumour cells of 30 clear cell, three chromophobic, and two chromophilic RCCs were completely devoid of CEACAM1. 15476270 Human
ceacam1 renal adenomas Renal adenomas also lacked CEACAM1 expression. 15476270 Human
ceacam1 tumour Thus, transient expression of the tumour suppressor CEACAM1 by tumour cells and subsequent homophilic interaction with CEACAM1 on tumour-infiltrating lymphocytes could represent a novel immune escape mechanism in RCC. 15476270 Human
ceacam1 melanoma CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. 15509546 Human
ceacam1 metastasis Expression of the cell adhesion molecule CEACAM1 in melanomas is an independent factor for the risk of metastasis with a predictive value superior to that of tumor thickness. 15509546 Human
ceacam1 melanomas Expression of the cell adhesion molecule CEACAM1 in melanomas is an independent factor for the risk of metastasis with a predictive value superior to that of tumor thickness. 15509546 Human
ceacam1 melanoma We have previously shown that CEACAM1 co-localizes at the tumor-stroma interface of invading melanoma masses with integrin beta(3) and that these two adhesion molecules interact via the CEACAM1 cytoplasmic domain. 15509546 Human
ceacam1 melanoma To address the functional consequences of CEACAM1 expression, we investigated invasion and migration of melanocytic and melanoma cells that stably express CEACAM1 using two different in vitro systems. 15509546 Human
ceacam1 melanomas These results strengthen the view that CEACAM1 and alpha(v)beta(3) integrin are functionally interconnected with respect to the invasive growth of melanomas. 15509546 Human
ceacam1 carcinomas CEACAM1 is a tumor suppressor whose expression is known to be lost in the great majority of early adenomas and carcinomas. 15568039 Human
ceacam1 adenomas CEACAM1 is a tumor suppressor whose expression is known to be lost in the great majority of early adenomas and carcinomas. 15568039 Human
ceacam1 tumor CEACAM1 is a tumor suppressor whose expression is known to be lost in the great majority of early adenomas and carcinomas. 15568039 Human
ceacam1 tumors We found that loss of CEACAM1 expression is more common in neoplastic tumors than APC mutations. 15568039 Human
ceacam1 hyperplastic polyps While APC function was normal in hyperplastic aberrant cypt foci and hyperplastic polyps, loss of CEACAM1 was observed as frequently as in the neoplasias. 15568039 Human
ceacam1 neoplasias While APC function was normal in hyperplastic aberrant cypt foci and hyperplastic polyps, loss of CEACAM1 was observed as frequently as in the neoplasias. 15568039 Human
ceacam1 hyperplastic While APC function was normal in hyperplastic aberrant cypt foci and hyperplastic polyps, loss of CEACAM1 was observed as frequently as in the neoplasias. 15568039 Human
ceacam1 tumors Moreover, the presence or absence of CEACAM1 expression in the hyperplastic tumors correlates with normal or reduced apoptosis, respectively. 15568039 Human
ceacam1 hyperplastic Moreover, the presence or absence of CEACAM1 expression in the hyperplastic tumors correlates with normal or reduced apoptosis, respectively. 15568039 Human
ceacam1 ht29 colon cancer Finally, in human HT29 colon cancer cells, apoptosis can be specifically restored by induction of CEACAM1 expression. 15568039 Human
ceacam1 neoplasia These data suggest an oncodevelopmental link between neoplasia and hyperplasia and demonstrate that CEACAM1 acts as a regulator of apoptosis in the colonic epithelium. 15568039 Human
ceacam1 hyperplasia These data suggest an oncodevelopmental link between neoplasia and hyperplasia and demonstrate that CEACAM1 acts as a regulator of apoptosis in the colonic epithelium. 15568039 Human
ceacam1 colon cancer Thus, failure of the maturing colon cell to express CEACAM1 is likely to contribute to the development of hyperplastic lesions, which may eventually pave the way to neoplastic transformation and colon cancer development. 15568039 Human
ceacam1 hyperplastic Thus, failure of the maturing colon cell to express CEACAM1 is likely to contribute to the development of hyperplastic lesions, which may eventually pave the way to neoplastic transformation and colon cancer development. 15568039 Human
ceacam1 hyperplastic polyps CEACAM1 and hyperplastic polyps: new links in the chain of events leading to colon cancer. 15602572 Human
ceacam1 colon cancer CEACAM1 and hyperplastic polyps: new links in the chain of events leading to colon cancer. 15602572 Human
ceacam1 transitional cell carcinoma in situ Here, we show that carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is expressed in umbrella cells of bladder urothelium but is down-regulated in superficial bladder cancer, such as histologic tumor stage a (pTa) and transitional cell c 15604255 Human
ceacam1 tumor Here, we show that carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is expressed in umbrella cells of bladder urothelium but is down-regulated in superficial bladder cancer, such as histologic tumor stage a (pTa) and transitional cell c 15604255 Human
ceacam1 superficial bladder cancer Here, we show that carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is expressed in umbrella cells of bladder urothelium but is down-regulated in superficial bladder cancer, such as histologic tumor stage a (pTa) and transitional cell c 15604255 Human
ceacam1 bladder cancer Mimicking the CEACAM1 down-regulation in the urothelium, CEACAM1 was silenced in bladder cancer cell lines 486p and RT4 using the small interfering RNA technique. 15604255 Human
ceacam1 bladder cancer Correspondingly, supernatants from the CEACAM1-overexpressing bladder cancer cell lines reduce, but those from CEACAM1 silencing induce endothelial tube formation and potentiate the morphogenetic effects of VEGF. 15604255 Human
ceacam1 bladder cancer CEACAM1 appears to be a promising endothelial target for bladder cancer therapy. 15604255 Human
ceacam1 tumor Here, we demonstrate the expression of carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) in angiogenic sprouts but not in large mother blood vessels within tumor tissue. 15536067 Human
ceacam1 tumor Thus, strategies targeting the endothelial up-regulation of CEACAM1 might be promising for antiangiogenic tumor therapy. 15536067 Human
ceacam1 gestational trophoblastic diseases Osteopontin Expression in Gestational Trophoblastic Diseases: Correlation With Expression of the Adhesion Molecule, CEACAM1. 15968204 Human
ceacam1 gestational trophoblastic disease CEACAM1 is an adhesion molecule, which we have recently found to be expressed at the maternal-fetal interface of the normal placenta with a localization to the extravillous (invasive) trophoblast and in gestational trophoblastic disease (GTD) and also to 15968204 Human
ceacam1 hydatidiform moles To analyze the expression of OPN, we performed immunohistochemistry on a total of 27 cases of GTD, including 21 hydatidiform moles and 6 choriocarcinomas, which had previously been characterized with respect to their CEACAM1 expression. 15968204 Human
ceacam1 choriocarcinomas To analyze the expression of OPN, we performed immunohistochemistry on a total of 27 cases of GTD, including 21 hydatidiform moles and 6 choriocarcinomas, which had previously been characterized with respect to their CEACAM1 expression. 15968204 Human
ceacam1 choriocarcinoma CEACAM1 had shown similar results and was found to be expressed in choriocarcinoma. 15968204 Human
ceacam1 gestational trophoblastic diseases The expression pattern of osteopontin in gestational trophoblastic diseases indicates that it might play a role in the pathogenesis of GTD (possibly as a functional complex with CEACAM1 and integrin beta3) and might be useful as an additional diagnostic m 15968204 Human
ceacam1 tumor BACKGROUND: Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a negative regulator of tumor cell growth, and may function as a tumor suppressor. 15952183 Human
ceacam1 hepatocellular carcinoma (hcc) The authors hypothesized that loss of CEACAM1 expression in hepatocellular carcinoma (HCC) cells may function as an adverse prognostic factor. 15952183 Human
ceacam1 tumor CEACAM1 expression in HCC was classified into two categories: diffuse expression, characterized by positive staining throughout the tumor specimen, or loss of expression, in which there were distinct areas of negative staining within the tumor specimen. 15952183 Human
ceacam1 hcc CEACAM1 expression in HCC was classified into two categories: diffuse expression, characterized by positive staining throughout the tumor specimen, or loss of expression, in which there were distinct areas of negative staining within the tumor specimen. 15952183 Human
ceacam1 tumor Loss of CEACAM1 expression was more frequent in tumor specimens with Edmondson-Steiner Grades III or IV (21 of 32 [66%]) than in tumor specimens with Grades I or II (5 of 107 [5%]; P < 0.001) and was always seen in areas with the highest histologic grade. 15952183 Human
ceacam1 tumor Loss of CEACAM1 expression was significantly associated with large tumor size, multiplicity of the tumor, portal vein invasion, and satellite nodules and affected survival adversely, according to univariate (P < 0.0001) and multivariate analyses (relative 15952183 Human
ceacam1 large tumor Loss of CEACAM1 expression was significantly associated with large tumor size, multiplicity of the tumor, portal vein invasion, and satellite nodules and affected survival adversely, according to univariate (P < 0.0001) and multivariate analyses (relative 15952183 Human
ceacam1 tumor CONCLUSIONS: Loss of CEACAM1 expression reflects aggressive tumor biology and thus indicates a poor prognosis for patients with HCC. 15952183 Human
ceacam1 hcc CONCLUSIONS: Loss of CEACAM1 expression reflects aggressive tumor biology and thus indicates a poor prognosis for patients with HCC. 15952183 Human
ceacam1 tumor Until now CEACAM1 is described to control cell proliferation, cell migration, tumor growth, angiogenesis and diverse leukocyte functions. 15909305 Human
cd66 myeloproliferative disorders In conclusion, abnormal CD14/CD66 co-expression might be a valuable parameter in defining asynchronous myelopoiesis in malignant myeloid disorders, especially myeloproliferative disorders and secondary acute myeloid leukemias. 9855250 Human
cd66 apl The induction of solitary expression of CD66c is a new finding which demonstrates As2O3 capability of generating phenotypic changes absolutely restricted to APL cells Moreover, these results provide experimental basis for considering the involvement of th 10674975 Human
cd66 aml CD66 was expressed in 2 of 29 patients with AML (acute myeloblastic leukemia) (6.8%) and in 8 of 12 patients with B-cell lineage ALL (66.7%; P<0.001); in blast crisis (BC) of chronic myelocytic leukaemia (CML), CD66 was expressed in two patients with lymp 10901608 Human
cd66 aml The CD66 expression is more frequent in ALL than in AML. 10901608 Human
cd66 mrd These findings suggest that an aberrant expression of CD66 could be used to investigate MRD in ALL. 10901608 Human
cd66 adult all The association between CD66 reactivity and bcr-abl in adult ALL remains to be investigated. 10901608 Human
cd66 hodgkin's disease Radiolabeled monoclonal antibodies have been used with encouraging results in conjunction with stem cell transplantation for patients with hematologic malignancies targeting a variety of surface antigens including CD33, CD45 and CD66 for leukemias, CD20 a 12058230 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.